Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares hit a new 52-week low on Tuesday . The company traded as low as GBX 2.70 ($0.03) and last traded at GBX 2.79 ($0.04), with a volume of 1444862 shares changing hands. The stock had previously closed at GBX 2.85 ($0.04).
Wall Street Analyst Weigh In
Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a research note on Thursday, January 2nd.
View Our Latest Report on POLB
Poolbeg Pharma Price Performance
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Read More
- Five stocks we like better than Poolbeg Pharma
- 3 REITs to Buy and Hold for the Long Term
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- How to Invest in Insurance Companies: A Guide
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Following Congress Stock Trades
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
